Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 18/20 | 0.75 |
| ▸ | PTGFR | P43088 | 1/20 | 0.39 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.39 |
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4785457 | 0.85 | GPBAR1 (1.00) | GPBAR1 | |
| SCHEMBL4739230 | 0.83 | GPBAR1 (0.74) | GPBAR1 | |
| SCHEMBL4743272 | 0.82 | GPBAR1 (0.76) | GPBAR1 | |
| SCHEMBL4741905 | 0.82 | GPBAR1 (1.00) | GPBAR1 | |
| SCHEMBL4740438 | 0.80 | GPBAR1 (0.75) | GPBAR1 | |
| SCHEMBL4740904 | 0.78 | GPBAR1 (0.75) | GPBAR1 | |
| SCHEMBL4741994 | 0.75 | GPBAR1 (0.87) | GPBAR1 | |
| SCHEMBL4739227 | 0.74 | GPBAR1 (1.00) | GPBAR1 | |
| SCHEMBL4740460 | 0.72 | GPBAR1 (0.82) | GPBAR1 | |
| SCHEMBL4739263 | 0.71 | GPBAR1 (0.81) | GPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221161-A1 | HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2008-09-11 | — | — | US | disclosed |
| US-20080221161-A1 | HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2008-09-11 | — | — | US | disclosed |
| US-20080221161-A1 | HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2008-09-11 | — | — | US | disclosed |
| WO-2008097976-A1 | HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008097976-A1 | HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221161-A1 | HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE | GPR119, GPBAR1, LDLR | GPBAR1 2/4885PTGFR 589/4885PTGER2 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.